CTOs on the Move

Oola Life

www.oolalife.com

 
Founded in 2012 by international bestselling authors, work-life balance experts, and holistic healthcare providers, Dr. Dave Braun and Dr. Troy Amdahl, Oola provides a simple and easy-to-follow lifestyle framework designed to lead you, step by step, to a life of less stress, more personal growth, and a clearer path toward living your unique purpose. The concept originally ideated in 1997 as Dr. Braun and Dr. Amdahl worked to better themselves in the seven key areas of life -- Fitness, Finance, Family, Field (career), Faith, Friends, and Fun. Since then, the Oola lifestyle has become a global phenomenon, with over a ...
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

Springmoor Retirement Community

Springmoor Retirement Community is one of the leading companies in Healthcare, Pharmaceuticals, and Biotech industry. Springmoor Retirement Community is based in Raleigh, NC. You can find more information on Springmoor Retirement Community at www.springmoor.com

Florida Emergency Physicians

Florida Emergency Physicians is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Maitland, FL. To find more information about Florida Emergency Physicians, please visit www.psrinc.net

Ipa Independent Pharmacy Co-op

Ipa Independent Pharmacy Co-op is a Cranbury, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Cayce's Pharmacy

Cayce's Pharmacy is a Hopkinsville, KY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Kolltan

Kolltan Pharmaceuticals is a private company founded in 2007 that is developing novel monoclonal antibody (mAb) drugs targeting receptor tyrosine kinases (RTKs). Kolltan's primary targets derive from seminal discoveries made in the laboratory of Dr. Joseph Schlessinger, Chairman of the Department of Pharmacology at the Yale School of Medicine, and in Kolltan’s laboratories. Dr. Schlessinger's laboratory has characterized a novel molecular mechanism underlying activation of RTKs providing, for the first time, a clear molecular explanation — at atomic resolution — for the oncogenic activity of mutations that have been identified in a variety of human cancers.